{"id":"NCT00327717","sponsor":"Eisai Inc.","briefTitle":"Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures","officialTitle":"A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2006-05-18","resultsPosted":"2014-08-15","lastUpdate":"2014-08-15"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Seizures"],"interventions":[{"type":"DRUG","name":"Zonisamide","otherNames":["Zonegran"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Zonisamide 100 mg tablet","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this trial are to evaluate the safety and efficacy of Zonisamide as adjunctive therapy in medically refractory patients receiving other antiepileptic drugs (AEDs).","primaryOutcome":{"measure":"Median Percent Change From Baseline in All Partial Seizure Frequency (Complex Partial Seizures (CP)+ Simple Partial Seizures (SP) + Secondary Generalization Seizures (SGS)) During the Fixed-dose Phase","timeFrame":"Baseline and 16 weeks","effectByArm":[{"arm":"Zonisamide 100 mg Tablet","deltaMin":-48.42,"sd":73.83},{"arm":"Placebo","deltaMin":-26.58,"sd":157.22}],"pValues":[{"comp":"OG000 vs OG001","p":"0.028"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":120},"commonTop":["somnolence","Upper respiratory tract infection","anorexia","Dizziness","nausea"]}}